You might think of cancer as a mass of rogue cells that grow uncontrollably. But cancer is more organized and strategic than ...

ZFTA–RELA is the cancer-promoting protein product of a gene fusion. Analyses of accessible sites in the DNA–protein complex chromatin in developing mice show that ZFTA–RELA binds to chromatin modules ...

Colorectal cancer is a malignant tumor of the colon or rectum, with approximately 150,000 new cases each year. Current treatment strategies, such as surgery, chemotherapy, radiotherapy, and ...

Immunotherapy, which uses programmed immune cells to selectively destroy cancer cells, has transformed cancer treatment. However, cancer cells have developed immune evasion strategies, leading to poor ...

Tumor cells can lapse into a sleep-like state and thereby evade the destructive effect of cancer drugs. In some types of the ...

Researchers at the University of Maryland School of Medicine (UMSOM) have identified a target that may improve the response to CAR T-cell therapy, a treatment for patients with recurrent or ...

Scientists at Pune's Agharkar Research Institute developed a nanomedicine targeting breast cancer cells by silencing key ...

Certain white blood cells in the immune system, known as neutrophils, can make cancer immunotherapy less effective, according ...

MultiValent Biotherapies, Inc. (MultiValent), a private biotechnology company developing targeted drug conjugate therapies for cancer, announced a $27.425 million first closing of its Series A ...